Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-12-2007 | Editorial

What can gallium-68 PET add to receptor and molecular imaging?

Authors: Adil AL-Nahhas, Zarni Win, Teresa Szyszko, Aviral Singh, Sameer Khan, Domenico Rubello

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2007

Excerpt

In the last decade there has been a significant increase in the development of radiolabelled peptides for diagnostic applications, especially due to simplified methods of purification. Peptides have fast clearance, rapid tissue penetration, and low antigenicity and can therefore be produced easily and inexpensively. In addition, if the diagnostic scan is positive, the peptides can be labelled with therapeutic radionuclides (yttrium-90, lutetium-177) and used for therapy [1]. …

Kwekkeboom DJ, Krenning EP. Peptide receptor imaging. In: Cook JR, Maisey MN, Britton KE, Chengazi V, editors. Clinical nuclear medicine, 4th edn. New York: Oxford University Press; 2006.

Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997;70:471–9.PubMed

Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63–70.PubMed

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRef

Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol 1999;10 Suppl 2:S17–21.PubMedCrossRef

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin tracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

de Jong M, Kwekkeboom DJ, Valkema R, Krenning EP. Endocrine: peptides. In: Cook JR, Maisey MN, Britton KE, Chengazi V, editors. Clinical nuclear medicine, 4th edn. New York: Oxford University Press; 2006.

Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumour uptake. J Nucl Med 1999;40:762–7.PubMed

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med 2006;36:228–47.PubMedCrossRef

10.

Green MS, Welch MJ. Gallium radiopharmaceutical chemistry. Int J Rad Appl Instrum B 1989;16:435–48.PubMed

11.

Hnatowich DJ. A review of radiopharmaceutical development with short-lived generator-produced radionuclides other than 99mTc. Int J Appl Radiat Isot 1977;28:169–81.PubMedCrossRef

12.

Hofmann M, Maecke H, Borner A, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.PubMedCrossRef

13.

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.PubMedCrossRef

14.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460–6.PubMedCrossRef

15.

Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115–22.PubMedCrossRef

16.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.PubMedCrossRef

17.

Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible role of ⁶⁸Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 2006;33:506.PubMedCrossRef

18.

Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P. ⁶⁸Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007;28:359–63.PubMedCrossRef

19.

Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 2005;19:145–63.PubMedCrossRef

20.

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Practical aspects of peptide receptor radionuclide therapy with [(177)Lu][DOTA0, Tyr3] octreotate. Q J Nucl Med Mol Imaging 2006;50:265–71.PubMed

21.

Koizumi M, Endo K, Kunimatsu M, Sakahara H, Nakashima T, Kawamura Y, et al. 67Ga-labeled antibodies for immunoscintigraphy and evaluation of tumor targeting of drug-antibody conjugates in mice. Cancer Res 1988;48:1189–94.PubMed

22.

Wagner SJ, Welch MJ. Gallium-68 labeling of albumin and albumin micro spheres. J Nucl Med 1979;20:428–33.PubMed

23.

Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317–25.PubMed

24.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S–6S.PubMed

25.

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9.PubMedCrossRef

26.

Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef

27.

Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.PubMedCrossRef

28.

Roivainen A, Tolvanen T, Salomäki S, Lendvai G, Velikyan I, Numminen P, et al. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 2004;45:347–55.PubMed

29.

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116–23.PubMed

30.

Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6–14) analog. J Nucl Med 2005;46:691–9.PubMed

31.

van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996;23:1508–13.PubMedCrossRef

32.

de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003;30:1134–9.PubMedCrossRef

33.

Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97–109.PubMedCrossRef

34.

Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radiol 2006;13:598–609.PubMedCrossRef

35.

Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 2005;46:354–64.PubMed

36.

Mäkinen TJ, Lankinen P, Pöyhönen T, Jalava J, Aro HT, Roivainen A. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2005;32:1259–68.PubMedCrossRef

37.

Breeman WAP, Verbruggen AM. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging 2007;34:978–81.PubMedCrossRef

Title: What can gallium-68 PET add to receptor and molecular imaging?
Authors: Adil AL-Nahhas
Zarni Win
Teresa Szyszko
Aviral Singh
Sameer Khan
Domenico Rubello
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0568-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

What can gallium-68 PET add to receptor and molecular imaging?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2007

A new PET tracer specific for vascular endothelial growth factor receptor 2

Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics

Can PET–CT with FDG replace contrast enhanced CT for imaging of liver metastases?

Radioiodine in the management of benign thyroid disease: clinical guidelines. Report of a Working Party, 2007. Royal College of Physicians (RCP)

Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT

Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction